Los Angeles Capital Management LLC Has $874,000 Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Los Angeles Capital Management LLC lifted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 49.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 514,377 shares of the biotechnology company’s stock after purchasing an additional 171,250 shares during the quarter. Los Angeles Capital Management LLC owned 0.34% of Heron Therapeutics worth $874,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Heron Therapeutics in the 3rd quarter valued at $31,000. Commonwealth Equity Services LLC raised its position in Heron Therapeutics by 5.5% in the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 16,467 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Heron Therapeutics by 5.8% during the third quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 19,345 shares during the period. Jacob Asset Management of New York LLC boosted its holdings in Heron Therapeutics by 18.2% during the third quarter. Jacob Asset Management of New York LLC now owns 327,450 shares of the biotechnology company’s stock valued at $337,000 after purchasing an additional 50,435 shares in the last quarter. Finally, Richmond Brothers Inc. grew its stake in shares of Heron Therapeutics by 142.9% in the 3rd quarter. Richmond Brothers Inc. now owns 103,009 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 60,604 shares during the period. 80.01% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HRTX shares. Capital One Financial began coverage on Heron Therapeutics in a research report on Tuesday, April 23rd. They set an “overweight” rating and a $6.00 target price for the company. StockNews.com raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a report on Wednesday.

Heron Therapeutics Price Performance

HRTX stock opened at $2.94 on Friday. The business has a fifty day moving average price of $2.73 and a 200 day moving average price of $2.09. Heron Therapeutics, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $3.22. The stock has a market capitalization of $442.87 million, a price-to-earnings ratio of -3.42 and a beta of 1.73.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.08. The business had revenue of $34.23 million during the quarter, compared to analyst estimates of $30.98 million. On average, equities analysts expect that Heron Therapeutics, Inc. will post -0.24 earnings per share for the current fiscal year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.